DUBLIN--(BUSINESS WIRE)--The "Data Sheet on Conjugate Vaccine Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
The global market for conjugate vaccines will expand at a CAGR of 14.6% to reach a value of USD 100.59 Bn by 2023.
Increased adoption of therapeutic vaccines for cancer, improved patient compliance, a larger product pipeline, and efforts to promote adoption of screening methods are some of the factors that will lead to the growth of the market. The Asia-Pacific market will exhibit the highest growth rate.
The vaccines are classified based on the diseases that they are target at - such as pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal, and others - and on the end users, into pediatric and adults. Technological advancements and regular vaccination programs by authorities are some of the factors that will help overcome the challenges posed by lack of awareness, shortages, uncertainty about future initiatives, and costs. Companies like GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, and Novartis are some of the major players operating in the market.
The subsequent information conveyed will be on an Excel sheet, presented in an easily identifiable format.
- Pfizer Inc.
- Merck & Co.
- Sanofi Pasteur
- CSL Limited
- Bharat Biotech International
- Biological E Limited
- Serum Institute of India
For more information about this report visit https://www.researchandmarkets.com/research/xhz3cc/data_sheet_on?w=4